In AML patients with TP53 mutations, who have a poor prognosis, DNA methyltransferase inhibitors activate endogenous retroviruses and trigger inflammasome signaling in a STING pathway-dependent manner59. The gene discussed is TP53; the disease is acute myeloid leukemia.